Srirupa Das, Associate Director, Medical Affairs, Tushar Fegade, Manager, Clinical Research Abbott Healthcare Private Limited, Mumbai.
|
|
- Laurel Gilbert
- 5 years ago
- Views:
Transcription
1 Indian Medical Gazette JUNE Comparative A Randomized, Open Label, Prospective, Comparative Evaluating the Efficacy and Safety of Fixed Dose Combination of Cefpodoxime 200 Mg + Clavulanic Acid 125 Mg Vs Cefpodoxime 200 Mg in Acute Bacterial Sinusitis Srirupa Das, Associate Director, Medical Affairs, Tushar Fegade, Manager, Clinical Research Abbott Healthcare Private Limited, Mumbai. Abstract Background: Fixed dose combination of cefpodoximeclavulanic acid and cefpodoxime both are commonly used in the treatment acute bacterial sinusitis. However, comparative clinical studies between the fixed dose combination of cefpodoxime-clavulanic acid versus cefpodoxime alone are not available. Objective: A postmarketing study was conducted to evaluate the efficacy and safety of fixed dose combination of cefpodoxime proxetil plus potassium clavulonate versus cefpodoxime proxetil in treatment of acute bacterial sinusitis. Material and methods: A total of 202 patients were enrolled in an open label, randomized, parallel group, two arms multicentric study. Patients were treated either with fixed dose combination of cefpodoxime 200 mg plus clavulanic acid 125 mg or cefpodoxime 200 mg; both given as one tablet twice daily for ten days. The efficacy was evaluated at baseline, day three, day five and day ten while the safety was assessed at screening and day 10. Statistical analysis: Intention to treat population was used to analyse the safety results while efficacy was evaluated in per protocol population. Chi square test was used to evaluate the efficacy parameters on six point Likert scale, global evaluation of efficacy and safety by investigators and patients. Results: Cure rate was higher in study group (58.43%) compared to control group (46.81%), however, the difference was not significant. No significant difference was seen in improvement and failure rate in both the groups (p=0.288). On day 3, rhinorrhea was either cured or much improved in significantly higher number of patients receiving study drug compared to control group (p=0.038). Global assessment of efficacy by patients significantly higher number of patients had excellent efficacy in the study group compared to control group (p=0.035) while no significant difference was seen in global efficacy assessment done by investigators. No patient reported serious adverse event in either groups. Conclusion: Rhinorrhea in acute bacterial sinusitis is relieved earlier by the combination of cefpodoxime plus potassium clavulonate compared to cefpodoxime alone. Efficacy of the combination is perceived as excellent by significantly more number of patients compared to cefpodoxime alone. Both the study drugs are well tolerated by patients. Keywords acute sinusitis, cefpodoxime, potassium clavulonate Introduction Community acquired respiratory tract infections like sinusitis are one of the most common reasons for the visiting physicians. The most important bacteria responsible for causing acute sinusitis are Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. It is difficult to establish the causative microorganism Address for correspondence: Mr. Tushar Fegade. Manager, Clinical Research, Medical Services Division, Abbott Healthcare Private Limited, Mumbai. tushar.fegade@abbott.com
2 226 Indian Medical Gazette JUNE 2015 responsible for acute bacterial sinusitis. Examination of infected fluid by sinus puncture is a painful method and not routinely done in clinical practice. Hence empirical treatment is usually selected based on the suspected bacterial aetiology. While selecting an antibiotic different parameters are considered including most likely pathogen, local pattern of antibiotic resistance, and pharmacological properties of the antibiotic 1. The increasing prevalence of antibiotic resistance is one of the major challenges worldwide 2. Increasing bacterial resistance has led to concerns about the current options for the empirical antibiotic use 1. Cefpodoxime proxetil is a third generation cephalosporin. It has activity against both gram positive and gram negative microorganisms 3. Cefpodoxime has shown good in vitro activity against respiratory pathogens like Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis 1. Cefpodoxime is most widely used in the treatment of respiratory tract infections 4. In clinical trials cefpodoxime proxetil is as effective as amoxicillin in the treatment of acute bacterial maxillary sinusitis 5. It is more effective than cefaclor in producing complete clinical cure in acute sinusitis 6. Cefpodoxime is useful in infections caused by bacteria resistant to penicillins and cephalosporins. However, resistance has been reported against cefpodoxime through beta-lactamase production 7. Clavulanic acid is a beta lactamase inhibitor which enhances activity of penicillin and cephalosporins against many resistant strains of bacteria 3. Clavulanic acid is an effective irreversible inhibitor of beta-lactamases of the Richmond types II, III, IV, and V 8. Potassium clavulanate is a beta lactamase inhibitor combined with cefpodoxime proxetil to overcome the betalactamase mediated bacterial resistance. Fixed dose combination (FDC) of cefpodoxime proxetil with potassium clavulanate is available and marketed in India. Objective The objective of this post-marketing (PMS) phase IV study was to evaluate the efficacy and safety of fixed dose combination of cefpodoxime proxetil 200 mg plus potassium clavulanate 125 mg vs cefpodoxime proxetil 200 mg in treatment of patients with acute bacterial sinusitis. Material and methods In this randomized, open label, comparative, parallel group, two arms, multicentric study adult patients (>18 years of age) of both sex suffering from acute bacterial sinusitis as evidenced by the symptoms of fever, headache, cough, nasal congestion, facial pain or tenderness or radiographic evidence were enrolled. Patients with chronic sinusitis (symptoms for > 4 weeks or >2 other episodes of acute sinusitis within previous 12 months), patients with a known allergy to any of ingredients of investigational product and/or comparator product, those requiring tranquilizers, having history of sinus surgery, cholestatic jaundice or hepatic dysfunction, epilepsy or seizures, requiring systemic antimicrobial agents therapy within 48 hrs of study entry were excluded from the study. Pregnant, lactating women and immunocompromized patients were also not included in the study. After satisfying inclusion and exclusion criteria and obtaining their written informed consent the patients were enrolled in the trial. The study was conducted in compliance with the ICMR guidelines for research on humans, declaration of Helsinki and Schedule-Y of drugs & cosmetics act (Jan 2005). The patients were allocated treatment to either of the two arms (study group or control group) as per predetermined randomization schedule. The patients in study group received fixed dose combination of cefpodoxime 200 mg plus clavulanic acid 125 mg, one tablet twice daily while the patients in control group received only cefpodoxime 200 mg, one tablet twice daily. The duration of treatment in both groups was ten days. Evaluation criteria: The primary end point of the study was clinical success rate at the End-of-Therapy (EOT) based on resolution of signs and symptoms observed on study entry. Clinical success was defined as cure plus improvement. Cure was defined as resolution of signs and symptoms to the level that existed prior to the occurrence of the acute illness with no worsening in the radiographic appearance of the sinuses and without requirement of antibiotics (other than the study drug) given for treatment of sinusitis while the improvement was defined as partial but incomplete resolution of the signs and symptoms of acute sinusitis and no requirement for additional antibiotic use. Failure was defined as persistence of one or more signs or symptoms of ABS or appearance of new signs or symptoms and/or a need for additional antimicrobials or change in antimicrobial therapy.
3 Indian Medical Gazette JUNE Clinical response of signs and symptoms was graded on four point scale (0-cured, 1- improved, 2-same and 3- worse). Signs and symptoms of acute bacterial sinusitis at each follow-up visit (Day 3, Day 5 and Day 10) were graded on 6 point Likert scale ( 1-cured, 2- much improved, 3-slightly improved, 4-same, 5-slightly worse and 6-much worse ). Efficacy was also measured by clinical success rates based on the global assessment of the clinical presentation of the subject made by the investigator as well as patient at the end of treatment on five point scale (excellent, very good, good, satisfactory and poor). Secondary end points included percentage of patients with resolution of sinusitis signs and symptoms at the EOT visit and incidence of treatment-emergent adverse events and changes in physical findings including vital signs from baseline through the end of therapy visit. The enrolled patients were followed up for assessing signs and symptoms i.e. efficacy parameters of acute bacterial sinusitis at baseline, day three, day five and day ten (End of therapy visit). The safety parameters were assessed at screening and day ten. Global assessment for efficacy and tolerability by investigator and patient was also assessed at day ten. Statistical analysis The safety evaluation was done in the Intention-to-treat (ITT) population. The ITT population included all patients who have taken at least one dose of study medication while efficacy was assessed in per protocol population i.e. those patients who completed the study. Paired t-test was performed to analyze the statistical significance between two groups for vital signs and other baseline parameters. Chi square test was used to evaluate the efficacy parameters on six point Likert scale and global evaluation of efficacy and safety by investigators and patients. A p value <0.05 was considered statistically significant. Results A total of 202 patients (100-study group; 102-control) from 8 centres were enrolled in the study out of which 183 patients completed the study. The reasons for noncompletion of 19 patients were loss to follow up (study group: 8, control: 6), request for withdrawal from study (study group and control 1each) and poor response (study group: 2, control: 1). Baseline characteristics: At baseline all the parameters were similar in both groups (p>0.05) (Table 1). There was no significant difference in vital parameters (pulse rate, systolic and diastolic blood pressure and temperature) and symptoms in both groups (Table 2) (t test p>0.05). Table 1 Baseline characteristics N Male 57 (57%) 56 (54.9%) Female 43 (43%) 46 (45.15%) Mean age (yrs) 31.9 (±12.1) 33.4 (±12.1) Mean weight (kg) 59.8 (±10.7) 59.3 (±11.7) Mean height (cm) (±8.9) (±9.7) Table 2 Baseline symptoms (n=100) (n=102) Subjective fever 2.94 (±3.24) 2.54 (±3.10) Nasal congestion 4.93 (±2.80) 5.00 (± 2.71) Headache 5.36 (±2.52) 5.12 (±2.77) Sinus pain 3.78 (±3.07) 3.64 (±2.95) Rhinorrhea 4.42 (±2.92) 4.14 (±2.88) Cough 3.60 (±3.07) 3.47 (±3.21) Maxillary toothache 0.85 (±2.26) 0.75 (±2.13) Energy level 1.95 (±2.52) 2.45 (±2.73) Difficulty sleeping 1.83 (±2.98) 2.37 (±3.30) Loss of appetite 1.41 (±2.63) 1.33 (±2.74) Efficacy Clinical response rate at the end of therapy i.e. at day ten is shown in the Fig. 1. Cure rate was numerically higher in study group compared to control group, however the difference was not significant. Similarly no significant difference was seen in improvement and failure rate in both the groups (chi square test p=0.288). On day 3, rhinorrhea was either cured or much
4 228 Indian Medical Gazette JUNE % 50.00% 40.00% 30.00% 20.00% 10.00% 0.00% Fig. 1 Clinical response rate (study group n=89; control group n=94) 58.43% 46.81% 37.08% 47.87% 4.49% 5.32% Cure Improvement Failure group group improved in significantly higher number of patients receiving study drug compared to control group (p=0.038). No significant difference was seen in any other symptom improvement on day three and day five (p>0.05) (Tables 3 and 4). On tenth day i.e. at the end of treatment, proportions of patients with resolution of most of the signs and symptoms were higher in study group compared with control group. However, the difference was not significant. There was trend of large number of patients showing improvement in headache with study drugs compared to control group (p=0.057) (Table 5). There was no significant difference in global assessment of efficacy between two groups as assessed by investigator (chi square test p=0.090; Fig. 2) % 30.00% 25.00% 20.00% 15.00% 10.00% 5.00% 0.00% Fig. 2 Global assessment of efficacy by investigator 33.71% Excellent 22.83% 34.78% 29.21% Very good group 16.85% Good 29.35% 15.73% Satisfactory 7.61% group 5.43% 4.49% Poor Table 3 Improvement in symptoms at day three Subjective fever Nasal congestion Headache Rhinorrhea Cough Cured % Much improved % Slightly improved % Same % Slightly worse % Much worse % P value
5 Indian Medical Gazette JUNE Table 4 Improvement in symptoms at day five Subjective fever Nasal congestion Headache Rhinorrhea Cough Table 5 Resolution of signs and symptoms on day ten Symptom group group Chi square test (p vale) Subjective fever 96.63% 97.87% Nasal congestion 65.17% 54.26% Headache 67.42% 61.70% Sinus pain 86.52% 79.79% Rhinorrhea 69.66% 60.64% Cough 70.79% 58.51% Maxillary toothache 92.13% 92.55% Energy level 67.42% 60.64% Difficulty sleeping 83.15% 84.04% Loss of appetite 82.02% 81.91% Cured % Much improved % Slightly improved % Same % Slightly worse % Much worse % P value Global assessment of efficacy by patients significantly higher number of patients had excellent efficacy in the study group compared to control group (chi square test p=0.035; Fig. 3). Safety assessment: A total of 8. 9% patients (study group 7% and control group 1.9%) reported adverse events (study group n=100; control group n=102). All the adverse events were mild in nature except one adverse event of moderate intensity in both groups (diarrhea in study group; vomiting in control group). No serious adverse events were reported by any of the patients during the study period. No significant difference was seen in the global assessment of tolerability evaluated by both an investigator (chi square test p=0.535) and patient (chi square test p=0.965) (Table 6). Discussion In primary care clinic, antibiotics are prescribed in about 85% to 98% of cases presenting with acute sinusitis 9. Generally antibiotics in acute sinusitis should be prescribed for ten to 14 days, or seven days after the patient is symptom free 10. In this study, cefpodoxime plus potassium clavulanate as well as cefpodoxime were given for ten days.
6 230 Indian Medical Gazette JUNE 2015 group Table 6 Global assessment of tolerability Investigator group (n=93) group Patient group (n=93) Good 97.75% 98.92% 97.75% 97.85% Moderate 2.25% 1.08% 2.25% 2.15% Poor % 35.00% 30.00% 25.00% 20.00% 15.00% 10.00% 5.00% 0.00% Fig. 3 Global assessment of efficacy by patient 32.58% Excellent 19.35% 36.56% 28.09% Very good group 16.85% Good 29.03% 17.98% Satisfactory 8.60% group 6.45% 4.49% Fixed dose combination of cefpodoxime proxetil 200 mg and potassium clavulanate 125 mg has showed higher clinical cure and improvement in the symptoms of lower respiratory tract infections compared to cefuroxime axetil 500 mg 2. However, there are no clinical studies comparing cefpodoxime plus potassium clavulanate versus cefpodoxime in acute bacterial sinusitis. On most of the efficacy and safety parameters cefpodoxime proxetil plus potassium clavulanate was found to be comparable to cefpodoxime proxetil alone. Though the significant difference was not seen, the cure rate was higher in patients who received cefpodoxime proxetil plus potassium clavulanate compared to control Poor group. Overall there was no significant difference in cure rate, improvement and failure rate in both the groups. Rhinorrhea is a bothersome symptom for the patients. Significantly higher number of patients receiving cefpodoxime proxetil plus potassium clavulanate showed improvement in rhinorrhea on day three compared to cefpodoxime alone (Table 3). Similarly, at the end of therapy visit, number of patients with resolution of nasal congestion, sinus pain, headache, cough and energy level with cefpodoxime proxetil plus potassium clavulanate were higher, compared to cefpodoxime alone (Table 5). However, the difference was not statistically significant. Patient satisfaction is important in any treatment for improved compliance and in turn better outcome. In this study, significantly higher number of patients had expressed the combination to be excellent in efficacy compared to cefpodoxime proxetil monotherapy. Tolerability of both the formulations was good. No patient reported serious adverse event in either groups. Open label study design and subjective evaluation of improvement are the limitations of this study. Larger studies are required to confirm the findings of our observation. Conclusion Rhinorrhea in acute sinusitis is relieved earlier by the combination of cefpodoxime plus potassium clavulonate compared to cefpodoxime alone. Efficacy of the combination is excellent as evaluated by significantly more number of patients compared to cefpodoxime alone. On other parameters of efficacy and safety, the combination is comparable to cefpodoxime monotherapy. Acknowledgement The authors thank all investigators for their contribution,
7 Indian Medical Gazette JUNE Dr. Deepak Langde for statistical analysis and Dr. Anant Patil for assistance in writing the manuscript. References 1. Cohen R. Clinical efficacy of cefpodoxime in respiratory tract infection. Journal of Antimicrobial Chemotherapy. 50; T1: 23-27, Awad N.T. Efficacy and Safety of Fixed Dose Combination of Cefpodoxime Proxetil and Potassium Clavulanate (Cefchamp) in Comparison with Cefuroxime Axetil in Patients with Lower Respiratory Tract Infections. Indian Medical Gazette , April Malathi S., Dubey R.N. and Venkarnarayanan R. Simultaneous RP-HPLC estimation of cefpodoxime proxetil and clavulonic acid in tablets. Indian J. of Pharm. Sci. 71; 1: , Todd W.M. Cefpodoxime proxetil: a comprehensive review. International Journal of Antimicrobial Agents. 4;1: 37-62, March Sydow C.V., Savolainen S., Soderqvist A. Treatment of Acute Maxillary Sinusitis Comparing Cefpodoxime Proxetil with Amoxicillin. Scandinavian Journal of Infectious Diseases. 27; 3: , Gehanno P., Depondt J., Barry B., Simonet M., Dewever H. Comparison of cefpodoxime proxetil with cefaclor in the treatment of sinusitis. J. Antimicrob. Chemother. 26 (suppl E): 87-91, Pennan M. Barry, Jeffrey D. Klausner. The use of cephalosporins for gonorrhea: The impending problem of resistance. Expert OpinPharmacother. 10(4): , March Neu H.C., Fu K.P. Clavulanic Acid, a Novel Inhibitor of f3-lactamases. Antimicrobial Agents and Chemotherapy. 14;5: , Nov Anon J.B., Jacobs M.R., Poole M.D., et al. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 130(Suppl 1):S1 45, Leung R.S., Katial R. The Diagnosis and Management of Acute and Chronic Sinusitis. Prim Care Clin Office Pract. 35: 11 24, 2008.
Clinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationAntibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?
Antibiotics & treatment of Acute Bcterial Sinusitis Walid Reda Product Manager Do your antimicrobial options meet your needs? Antimicrobial Effects: What s involved? Effect in Humans: Serum concentration
More informationPrescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children
Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children Prescribing Antimicrobials for Common Illnesses When treating common illnesses such as ear infections and strep throat,
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationClinical efficacy of cefpodoxime in respiratory tract infection
Journal of Antimicrobial Chemotherapy (2002) 50, Topic T1, 23 27 DOI: 10.1093/jac/dkf805 Clinical efficacy of cefpodoxime in respiratory tract infection Robert Cohen* Department of Microbiology, Intercommunal
More informationRational use of antibiotic in upper respiratory tract infection (URI) and community acquired pneumonia รศ.จามร ธ รตก ลพ ศาล 23 พฤษภาคม 2550
Rational use of antibiotic in upper respiratory tract infection (URI) and community acquired pneumonia รศ.จามร ธ รตก ลพ ศาล 23 พฤษภาคม 2550 Sinusitis Upper respiratory tract infections (URI) Common cold
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationComparison of cefpodoxime proxetil with cefaclor in the treatment of sinusitis
Journal of Antimicrobial Chemotherapy () 6, Suppl. E, 87- Comparison of cefpodoxime proxetil with cefaclor in the treatment of sinusitis P. Gehanno", J. Depondt", B. Barry", M. Simonet* and H. Dewever"
More informationPharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J
Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J Record Status This is a critical abstract of an economic evaluation
More informationSynopsis. Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets
Synopsis Name of the sponsor Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets Name of active ingredient Title of the study Study
More informationLet me clear my throat: empiric antibiotics in
Let me clear my throat: empiric antibiotics in respiratory tract infections Alexander John Langley, MD MS MPH Goals of this talk Overuse of antibiotics is a major issue, as a result many specialist medical
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationPhase III Clinical Trial of Moxifloxacin Hydrochloride in the Treatment of Acute Exacerbations of Chronic Bronchitis in Comparison with Azithromycin
ORIGINAL ARTICLE JIACM 2002; 3(4): 360-6 Phase III Clinical Trial of Moxifloxacin Hydrochloride in the Treatment of Acute Exacerbations of Chronic Bronchitis in Comparison with Azithromycin SH Talib*,
More informationSimplicef is Used to Treat Animals with Skin Infections
Simplicef is Used to Treat Animals with Skin Infections PRODUCT INFO Simplicef tablets are a semi-synthetic cephalosporin antibiotic cefpodoxime proxetil used to cure infections caused by the susceptible
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationUpdated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007
Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007 1 Ongoing data from CDC 's Gonococcal Isolate Surveillance Project (GISP), including
More informationSuitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP)
STUDY PROTOCOL Suitability of Antibiotic Treatment for CAP (CAPTIME) Purpose The duration of antibiotic treatment in community acquired pneumonia (CAP) lasts about 9 10 days, and is determined empirically.
More informationScholars Research Library. Investigation of antibiotic usage pattern: A prospective drug utilization review
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2011: 3 (5) 301-306 (http://scholarsresearchlibrary.com/archive.html) ISSN 0974-248X USA CODEN: DPLEB4
More informationPharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements
Pharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements should be avoided. PDR Drug Summaries are concise point-of-care
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
More informationBacterial skin and soft tissues infections (SSTI) are one of the most common 1. infections among different age groups
Bacterial skin and soft tissues infections (SSTI) are one of the most common 1 infections among different age groups Gram-positive bacteria are the most frequently isolated pathogens from SSTI, with a
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationObjective 1/20/2016. Expanding Antimicrobial Stewardship into the Outpatient Setting. Disclosure Statement of Financial Interest
Expanding Antimicrobial Stewardship into the Outpatient Setting Michael E. Klepser, Pharm.D., FCCP Professor Pharmacy Practice Ferris State University College of Pharmacy Disclosure Statement of Financial
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #65 (NQF 0069): Appropriate Treatment for Children with Upper Respiratory Infection (URI) National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationIs amoxicillin good for viral infections
Is amoxicillin good for viral infections 19-6-2017 Is Amoxicillin Good For Throat Infection. They will not help sore throats caused by allergies or viral infections such as colds amoxicillin is. Reviews
More informationReceived: Accepted: Access this article online Website: Quick Response Code:
Indian Journal of Drugs, 2016, 4(3), 69-74 ISSN: 2348-1684 STUDY ON UTILIZATION PATTERN OF ANTIBIOTICS AT A PRIVATE CORPORATE HOSPITAL B. Chitra Department of Pharmacy Practice, College of Pharmacy, Sri
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #65 (NQF 0069): Appropriate Treatment for Children with Upper Respiratory Infection (URI) National Quality Strategy Domain: Efficiency and Cost Reduction Meaningful Measure Area: Appropriate
More informationAmoxicillin clavulanic acid spectrum
Cari untuk: Cari Cari Amoxicillin clavulanic acid spectrum 14-8-2017 Amoxicillin and clavulanate potassium (AMC), also known as augmentin, is an antibiotic used to treat bacterial infections. AMC is available
More informationLefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results. September 18, 2017
Lefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results September 18, 2017 Safe Harbor and Disclaimer Any statements in this presentation about future expectations, plans and prospects
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationRational management of community acquired infections
Rational management of community acquired infections Dr Tanu Singhal MD, MSc Consultant Pediatrics and Infectious Disease Kokilaben Dhirubhai Ambani Hospital, Mumbai Why is rational management needed?
More informationCME/CE QUIZ CME/CE QUESTIONS. a) 20% b) 22% c) 34% d) 35% b) Susceptible and resistant strains of typical respiratory
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for
More informationAcute Pyelonephritis POAC Guideline
Acute Pyelonephritis POAC Guideline Refer full regional pathway http://aucklandregion.healthpathways.org.nz/33444 EXCLUSION CRITERIA: COMPLICATED PYELONEPHRITIS Discuss with relevant specialist for advice
More information3/23/2017. Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc. Kathryn G. Smith: Nothing to disclose
Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc Kathryn G. Smith: Nothing to disclose Describe the new updates and rationale for them Relay safety concerns with use of
More informationSafety of an Out-Patient Intravenous Antibiotics Programme
Safety of an Out-Patient Intravenous Antibiotics Programme Chan VL, Tang ESK, Leung WS, Wong L, Cheung PS, Chu CM Department of Medicine & Geriatrics United Christian Hospital Outpatient Parental Antimicrobial
More informationVolume. December Infection. Notes. length of. cases as 90% 1 week. tonsillitis. First Line. sore throat / daily for 5 days. quinsy >4000.
Volume 8; Number 22 LINCOLNSHIRE GUIDELINES FOR THE TREATMENT OF COMMONLYY OCCURRING INFECTIONS IN PRIMARY CARE: WINTER 2014/15 In this issue of the PACE Bulletin we present an update of our Guidelines
More informationECHO: Management of URIs. Charles Krasner, M.D. Sierra NV Veterans Affairs Hospital University of NV, Reno School of Medicine October 16, 2018
ECHO: Management of URIs Charles Krasner, M.D. Sierra NV Veterans Affairs Hospital University of NV, Reno School of Medicine October 16, 2018 Infectious causes of URIs change over time Most ARIs are viral
More informationAntibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Antibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Sung Kyu Kim, M.D.Young Sam Kim, M.D. Department of Internal Medicine Yonsei University College of Medicine,
More informationShort Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/ Clavulanate and Cefuroxime Axetil
Short Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/ Clavulanate and Cefuroxime Axetil D. Adam, MD PhD, Munich, Germany H. Scholz, MD PhD, Berlin,
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationCritical Appraisal Topic. Antibiotic Duration in Acute Otitis Media in Children. Carissa Schatz, BSN, RN, FNP-s. University of Mary
Running head: ANTIBIOTIC DURATION IN AOM 1 Critical Appraisal Topic Antibiotic Duration in Acute Otitis Media in Children Carissa Schatz, BSN, RN, FNP-s University of Mary 2 Evidence-Based Practice: Critical
More informationReduce the risk of recurrence Clear bacterial infections fast and thoroughly
Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Clearly advanced 140916_Print-Detailer_Englisch_V2_BAH-05-01-14-003_RZ.indd 1 23.09.14 16:59 In bacterial infections, bacteriological
More informationGLOBAL ANTIBIOTIC RESEARCH & DEVELOPMENT PARTNERSHIP
GLOBAL ANTIBIOTIC RESEARCH & DEVELOPMENT PARTNERSHIP CO-AMOXICLAV (AMOXICILLIN + CLAVULANATE) Dr. Marie-Claude BOTTINEAU Dr. Emmanuel BARON Summary of global estimates (CHERG 2013) ~ 6.6 million deaths
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More information11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1
Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director
More informationPerichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV
Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationORIGINAL INVESTIGATION. Doxycycline Is a Cost-effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia
ORIGINAL INVESTIGATION Doxycycline Is a Cost-effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia Reba K. Ailani, MD; Gautami Agastya, MD; Rajesh K. Ailani, MD; Beejadi N. Mukunda,
More informationCLINICAL USE OF BETA-LACTAMS
CLINICAL USE OF BETA-LACTAMS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu WHY IS INFECTIOUS DISEASE PHARMACOTHERAPY SO CONFUSING? Microbial
More informationQuality ID #66: Appropriate Testing for Children with Pharyngitis National Quality Strategy Domain: Efficiency and Cost Reduction
Quality ID #66: Appropriate Testing for Children with Pharyngitis National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More informationNewsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017
Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Fluoroquinolones Newsflash: Fluoroquinolones Don t
More informationCLINICAL AUDIT. Prescribing amoxicillin clavulanate appropriately
CLINICAL AUDIT Prescribing amoxicillin clavulanate appropriately Valid to September 2018 bpac nz better medicin e Background Amoxicillin clavulanate is a broad spectrum antibiotic used in primary care
More informationparameters were enhanced to develop new antimicrobial formulations CONSIDERATIONS IN ANTIMICROBIAL SELECTION Using animal models and human data, PK an
Overview of Newer Antimicrobial Formulations for Overcoming Pneumococcal Resistance William A Craig, MD The pharmacokinetic (PK) and pharmacodynamic (PD) profile of an antimicrobial agent provides important
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active
More informationPATIENT INFORMATION LEAFLET DYNA CEFPODOXIME 100 mg / DYNA CEFPODOXIME SUSPENSION:
SCHEDULING STATUS S4 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DYNA CEFPODOXIME 100 mg (film coated tablet) DYNA CEFPODOXIME SUSPENSION (powder for oral suspension) Please read this leaflet carefully
More informationHost, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus
Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Montana ACP Meeting 2018 September 8, 2018 Staci Lee, MD, MEHP Billings
More informationchoice The Rilexine Palatable Tablets First generation cephalosporin for skin infections Now registered for ONCE daily administration*
Virbac Dermatology Palatable Tablets The choice First generation cephalosporin for skin infections Now registered for ONCE daily administration* are only available under Veterinary Authorisation. www.virbac.co.nz
More informationGuidelines for Treatment of Urinary Tract Infections
Guidelines for Treatment of Urinary Tract Infections Overview This document details the Michigan Hospital Medicine Safety (HMS) Consortium preferred antibiotic choices for treatment of uncomplicated and
More informationAntimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS
Antimicrobial Stewardship in the Long Term Care and Outpatient Settings Carlos Reyes Sacin, MD, AAHIVS Disclosure Speaker and consultant in HIV medicine for Gilead and Jansen Pharmaceuticals Objectives
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #66: Appropriate Testing for Children with Pharyngitis National Quality Strategy Domain: Efficiency and Cost Reduction Meaningful Measure Area: Appropriate Use of Healthcare 2019 COLLECTION
More informationOutpatient Antimicrobial Stewardship. Jeffrey S Gerber, MD, PhD Division of Infectious Diseases The Children s Hospital of Philadelphia
Outpatient Antimicrobial Stewardship Jeffrey S Gerber, MD, PhD Division of Infectious Diseases The Children s Hospital of Philadelphia Overview The case for outpatient antimicrobial stewardship Interventions
More informationInteractive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe
Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Pneumonia Community Acquired Pneumonia 1) Is it pneumonia? ie new symptoms and signs of
More information10/9/2017. Evidence-Based Interventions to Reduce Inappropriate Prescription of Antibiotics. Prescribing for Respiratory Tract Infections
Evidence-Based Interventions to Reduce Inappropriate Prescription of Antibiotics Ann Thomas, MD, MPH Oregon Public Health Division Prescribing for Respiratory Tract Infections Antibiotic use is primary
More informationRandomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis
Randomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis Steve SM Wong Alice Ho Miu Ling Nethersole Hospital Background PD peritonitis is a major cause of PD
More informationComparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle
Treatment Study DRAXXIN vs. Nuflor July 2005 Comparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle Pfizer Animal Health, New York,
More informationBELIEFS AND PRACTICES OF PARENTS ON THE USE OF ANTIBIOTICS FOR THEIR CHILDREN WITH UPPER RESPIRATORY TRACT INFECTION
PIDSP Journal 2009 Vol 10No.1 Copyright 2009 BELIEFS AND PRACTICES OF PARENTS ON THE USE OF ANTIBIOTICS FOR THEIR CHILDREN WITH UPPER RESPIRATORY TRACT INFECTION Micheline Joyce C. Salonga, MD* ABSTRACT
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationAntibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents
Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique
More informationAntimicrobial Stewardship in Continuing Care. Urinary Tract Infections Clinical Checklist
Antimicrobial Stewardship in Continuing Care Urinary Tract Infections Clinical Checklist December 2014 What is Antimicrobial Stewardship? Using the: right antimicrobial agent for a given diagnosis at the
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Community Acquired 1) Is it pneumonia? ie new symptoms and signs of a lower respiratory
More informationAntibiotic stewardship in long term care
Antibiotic stewardship in long term care Shira Doron, MD Associate Professor of Medicine Division of Geographic Medicine and Infectious Diseases Tufts Medical Center Boston, MA Consultant to Massachusetts
More informationAmoxicillin Introduction: Mechanism of action: Pharmacology: Indications: Dosage: 12 Weeks ( 3 Months):
Amoxicillin Introduction: A semisynthetic antibiotic, an analog of ampicillin, with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microganisms. Mechanism of action:
More informationAntimicrobial Resistance Update for Community Health Services
Antimicrobial Resistance Update for Community Health Services Elizabeth Beech Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England October 2015 elizabeth.beech@nhs.net Superbugs
More informationJMSCR Vol 05 Issue 03 Page March 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i3.219 Comparative Study of Adverse Effect of
More informationUnasyn alternative if penicillin allergic
Unasyn alternative if penicillin allergic The following guidelines have been developed to assist physicians with the appropriate selection of prophylactic and empiric antibiotic therapy for potential and.
More informationDoxycycline for strep pneumonia
Doxycycline for strep pneumonia Antibiotic Levofloxacin (Levaquin) 750 mg, 500 mg for the treatment of respiratory, skin, and urinary tract infections, user reviews and ratings. 14-12-1995 John G. Bartlett,
More informationLyme disease: diagnosis and management
National Institute for Health and Care Excellence Final Lyme disease: diagnosis and management [D] Evidence review for the management of erythema migrans NICE guideline 95 Evidence review April 2018 Final
More informationDelayed Prescribing for Minor Infections Resource Pack for Prescribers
Delayed Prescribing for Minor Infections Resource Pack for Prescribers Background: Antibiotic resistance is an alarming threat to modern healthcare, and infectious illness remains a major global threat
More informationKeywords: amoxicillin/clavulanate, respiratory tract infection, antimicrobial resistance, pharmacokinetics/pharmacodynamics, appropriate prescribing
Journal of Antimicrobial Chemotherapy (2004) 53, Suppl. S1, i3 i20 DOI: 10.1093/jac/dkh050 Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review
More informationIncidence of hospital-acquired Clostridium difficile infection in patients at risk
Baptist Health South Florida Scholarly Commons @ Baptist Health South Florida All Publications 5-20-2016 Incidence of hospital-acquired Clostridium difficile infection in patients at risk Christine Ibarra
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationS aureus infections: outpatient treatment. Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium
S aureus infections: outpatient treatment Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium Intern Med J. 2005 Feb;36(2):142-3 Intern Med J. 2005 Feb;36(2):142-3 Treatment of
More informationAntibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco
Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance
More informationINFECTIONS IN CHILDREN-ANTIMICROBIAL MANAGEMENT
INFECTIONS IN CHILDREN-ANTIMICROBIAL MANAGEMENT Name & Title Of Authors: Dr M Milupi, Consultant Microbiologist Dr N Rao,Consultant Paediatrician Dr V Desai Consultant Paediatrician Date Revised: DEC 2015
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationSurgical prophylaxis for Gram +ve & Gram ve infection
Surgical prophylaxis for Gram +ve & Gram ve infection Professor Mark Wilcox Clinical l Director of Microbiology & Pathology Leeds Teaching Hospitals & University of Leeds, UK Heath Protection Agency Surveillance
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationTreating Rosacea in the Era of Bacterial Resistance. This presentation is sponsored by Galderma Laboratories, L.P.
Treating Rosacea in the Era of Bacterial Resistance This presentation is sponsored by Galderma Laboratories, L.P. Lecture Discuss rosacea as an inflammatory condition Assess the psychosocial impact of
More informationStudies on Antimicrobial Consumption in a Tertiary Care Private Hospital, India
Human Journals Research Article April 2016 Vol.:6, Issue:1 All rights are reserved by Zarine Khety et al. Studies on Antimicrobial Consumption in a Tertiary Care Private Hospital, India Keywords: Drug
More informationInvasive Group A Streptococcus (GAS)
Invasive Group A Streptococcus (GAS) Cause caused by a bacterium commonly found on the skin and in the throat transmitted by direct, indirect or droplet contact with secretions from the nose, and throat
More informationAntimicrobial prescribing pattern in acute tonsillitis: A hospital based study in Ajman, UAE
Antimicrobial prescribing pattern in acute tonsillitis: A hospital based study in Ajman, UAE Lisha Jenny John 1*, Meenu Cherian 2, Jayadevan Sreedharan 3, Tambi Cherian 2 1 Department of Pharmacology,
More informationRole of Moxifloxacin in Bacterial Keratitis
Original Article Role of Moxifloxacin in Bacterial Keratitis Aamna Jabran, Aurengzeb Sheikh, Syed Ali Haider, Zia-ud-din Shaikh Pak J Ophthalmol 29, Vol. 25 No. 2.................................................................................
More informationCommunity-Associated C. difficile Infection: Think Outside the Hospital. Maria Bye, MPH Epidemiologist May 1, 2018
Community-Associated C. difficile Infection: Think Outside the Hospital Maria Bye, MPH Epidemiologist Maria.Bye@state.mn.us 651-201-4085 May 1, 2018 Clostridium difficile Clostridium difficile Clostridium
More information